大剂量瑞舒伐他汀对急性心肌梗死患者血清高敏 C反应蛋白、MMP-9及心功能的影响

摘要

Aim:To investigate the effect of large dose of rosuvastatin on the levels of serum high-sensitivity C-reactive protein(hs-CRP),matrix metallo-proteinase 9(MMP-9) and cardiac function in patients with acute myocardial infarction (AMI).Methods:Seventy patients with AMI were allocated into conventional-dose rosuvastatin (10 mg/d) group (control group) and large-dose rosuvastatin group (20 mg/d) at random.The serum levels of MMP-9 and hs-CRP were measured within 24 hours and 12 weeks after treatment, respectively.LVEDD,LVESD, LVEF,FS,and VE/VA were measured within 24 hours and 20 weeks after treatment using transthoracic Doppler echocardiography , respectively .Results: Compared with the control group ,the changes of the serum levels of hs-CRP and MMP-9 and those of LVESD ,LVEDD,LVEF,FS,VE/VA between the 2 time points in the large-dose rosuvastatin group was significantly different ( t=6.578,12.595,4.813, 6.339,6.313,15.148 and 6.472,P<0.05).Conclusion: Large dose rosuvastatin could inhibit ventricular remodeling , improve cardiac function and long-term prognosis of AMI patients .%目的：观察大剂量瑞舒伐他汀对急性心肌梗死（AMI）患者血清高敏C反应蛋白（hs-CRP）、基质金属蛋白酶-9（MMP-9）及心功能的影响。方法：70例AMI患者分为瑞舒伐他汀（10 mg/d）常规剂量治疗组和瑞舒伐他汀（20 mg/d）大剂量治疗组，每组35例。2组均在治疗24 h、12周抽取患者静脉血，ELISA法检测血清hs-CRP、MMP-9水平；应用超声心动图分别于治疗24 h、20周测量患者左室收缩末内径（ LVESD）、左室舒张末内径（ LVEDD）、左室射血分数（LVEF）、左室短轴缩短分数（FS）、心室舒张早期左房室瓣血流峰值流速/心室舒张晚期左房室瓣血流峰值流速（ VE/VA）。结果：2组患者治疗24 h和12周血清hs-CRP、MMP-9水平差值，治疗24 h和20周LVESD、LVEDD、LVEF、FS、VE/VA差值的比较差异均有统计学意义（t＝6．578、12．595、4．813、6．339、6．313、15．148和6．472，P均＜0．05）。结论：大剂量瑞舒伐他汀可有效抑制 AMI患者的心室重构，改善心脏功能，其效应较常规剂量增强。